Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on cholesterol and glucose fluxes in uncomplicated type 2 diabetes
NL-OMON28993Active, not recruiting
- Sponsor
- AMC Health
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and dyslipidemia, sponsored by AMC Health. Primary endpoint: Effect of 5 weeks of SGLT2 inhibition on LDL cholesterol synthesis. Started Sep 2016; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NL-OMON28993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28993.